Halda Therapeutics

Executive Summary

Halda Therapeutics is a preclinical-stage biotechnology company developing a novel class of small molecule therapeutics that modulate protein degradation via a unique mechanism, targeting previously undruggable oncoproteins. Founded in 2019 and headquartered in New Haven, CT, the company has raised $126 million to advance its proprietary platform, which aims to overcome the limitations of traditional targeted therapies and first-generation protein degraders. Halda's approach focuses on induced proximity to drive selective degradation of disease-relevant proteins, potentially offering transformative treatment options for a broad range of cancers. The company's platform is designed to address challenging targets that have eluded conventional drug discovery, positioning it as a potential leader in the next wave of targeted oncology therapies. Halda Therapeutics is actively advancing its lead pipeline programs toward clinical development. The company's most advanced candidate is expected to enter the clinic in the near term, with key inflection points including IND filing and initiation of Phase 1 trials. Given the substantial funding and innovative platform, Halda is well-positioned to generate proof-of-concept data in patients. The primary risk remains the preclinical nature of the programs and the inherent uncertainties of early-stage drug development. However, the significant unmet need in oncology and the unique mechanism of action provide a strong rationale for the company's approach.

Upcoming Catalysts (preview)

• Q2 2027IND filing for lead program60% success
• Q4 2027Initiation of Phase 1 clinical trial50% success
• Q1 2027Presentation of preclinical data at major conference80% success